My Cart [ 0 ]
Home > Chemicals > Inhibitors, Activators, Antagonists, and Agonists > A-Z Inhibitors, Activators, Antagonists, and Agonists > VX-765

VX-765

Catalog No. Product Name Size List Price (US$) Quantity
APIM050366 VX-765 5 mg 110.00
APIM050366 VX-765 10 mg 150.00
APIM050366 VX-765 50 mg 420.00
APIM050366 VX-765 100 mg 720.00
APIM050366 VX-765 200 mg 1200.00
Description

Background Information:

VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy, currently being developed by Vertex.  VX-765 is an orally-absorbed pro-drug of VRT-043198, a potent and selective inhibitor of ICE/caspase-1 sub-family caspases.  VRT-043198 exhibits 100-10,000-fold selectivity against other caspase-3 and -6-9.  In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of Interleukin (IL)-1beta and IL-18, but had little effect on the release of several other cytokines, including IL-1alpha, tumor necrosis factor-alpha, IL-6 and IL-8.

Reference:

1.  Boxer, Matthew B.; Quinn, Amy M.; Shen, Min; Jadhav, Ajit; Leister, William; Simeonov, Anton; Auld, Douglas S.; Thomas, Craig J. A Highly Potent and Selective Caspase 1 Inhibitor that Utilizes a Key 3-Cyanopropanoic Acid Moiety. ChemMedChem (2010), 5(5), 730-738.  
2. Eda, Hiroyuki. Therapeutic potential for caspase inhibitors: Present and future. Design of Caspase Inhibitors as Potential Clinical Agents (2009), 251-287.  

APIM050366: VX-765

CAS No.: 273404-37-8.
Molecular Formula: C24H33ClN4O6.
Molecular Weight: 508.99.
Purity: 99% chem. and stereomeric purity (HPLC and Chiral HPLC).
QC: HPLC-MS, 1HNMR, Chiral HPLC, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.

Related Links

See our Privacy Policy